publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
Edoxaban
Incidence and predictors of worsening renal function in edoxaban-treated atrial fibrillation patients within ETNA-AF-Europe registry
R-DXd
Raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models
Valemetostat
Mechanisms of action and resistance in histone methylation-targeted therapy
Pexidartinib
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Edoxaban
Prescribing patterns and outcomes of edoxaban in atrial fibrillation patients from Asia — one-year data from the Global ETNA-AF program
HER3-DXd
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
Other/Multi
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: A multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
Edoxaban
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study
Edoxaban
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: Patient characteristics from the prospective observational ETNA-AF-China registry
Edoxaban
Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial